DOCSLIB.ORG

Global Vaccine Action Plan Monitoring, Evaluation & Accountability Secretariat Annual Report 2016 © World Health Organization 2016

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Global Vaccine Action Plan Monitoring, Evaluation & Accountability Secretariat Annual Report 2016 © World Health Organization 2016 Global Vaccine Action Plan Monitoring, Evaluation & Accountability Secretariat Annual Report 2016 © World Health Organization 2016 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate borderlines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. Layout: www.paprika-annecy.com Global Vaccine Action Plan Monitoring, Evaluation & Accountability Secretariat Annual Report 2016 page IV Acknowledgements Data analysis Sherene Agama, Olivier Beauvais, Hemanthi Mariat, Kamel Senouci, Claudia Catherine-Steulet, Dassanayake-Nicolas, Laure Dumolard, Ajay Kumar Robert Totanes, Daniela Urfer Goel, Anwesha Majumder, Nikhil Mandalia, Stephanie Technical input Nihal Abeysinghe, Kaushik Banerjee, Sunil Bahl, Noni MacDonald, Yvette Madrid, Samya Mandal, Ram Madhava Balakrishnan, Lahouari Belgharbi, Melissa Malhame, Stephanie Mariat, Balcha Masresha, Oleg Benes, Deborah Bettels, Pamela Bravo, Logan Cuauhtemoc Ruiz Matus, Andrew Meek, Ravi Menon, Brenzel, Robb Butler, Niyazi Cakmak, Tania Cernuschi, Richard Mihigo, Annie Moe, Suerie Moon, Liudmila Alireza Khadem Broojerdi, Thomas Cherian, Mosina, Alice Abou Nader, Patrick O’Connor, Hiromasa Adam Cohen, Santiago Cornejo, Amy Dietterich, Okayasu, Desiree Pastor, Robert Perry, Susan Perez, Sergey Diorditsa, Philippe Duclos, Laure Dumolard, Samina Piracha, Claudio Politi, Mohamed Refaat, Rudi Eggers, Ebru Ekeman, Kate Elder, Lauren Franzel, Azhar Abid Reza, Daniel Rodriguez, Oliver Rosenbauer, Michael Free, Samir El Hemsy, John Fitzsimmons, Paul Rutter, Jeffrey Safrit, Vaseeharan Sathiyamoorthy, Andrew Ford, Martin Friede, Aurelia Gasca, Lewis Schrager, Benjamin Schreiber, Melanie Schuster, Sy Gebrekidan, Birgitte Giersing, Shawn Gilgrist, William Schluter, Baqar Shahida, Kamel Senouci, Jan Grevendonk, Isaac Gobina, Lee Hall, Peter Hansen, Liane Smith, Peter Strebel, Yoshihiro Takashima, Brian Tine Hein, Carmen Rodriguez Hernandez, Joachim Taliesin, Nadia Teleb, Nancy Touchette, Hapsatou Hombach, Ahmadreza Hosseinpoor, Angela Hwang, Toure, Nathalie Van De Maele, Kirsten Vannice, Johan Dragan Jankovic, Jim Janimak, Courtney Jarrahian, Vekemans, Martha Velandia, Michael Ward, Annie Anna-Lea Kahn, Sudhir Khanal, Debbie Kristensen, Rein-Weston, Michael Wong, Greg Widmyer, Ahmadu Christine Lamoureux, Tina Lorenson, Patrick Lydon, Yakubu, Darin Zehrung, Patrick Zuber Denis Maire, Nikhil Mandalia, Carsten Mantel, page V Reviewers • For the Research and Development GVAP Indicators: Helen Rees, David Salisbury, Budihardja Singgih, Salim Abdulla, Ashish Bavdekar, Klaus Cichutek, Qinjian Zhao Bernard Fritzell, Barney Graham, Ruth Karron, David Kaslow, Claudio Lanata, Mair Powell, Peter Smith, Yiming Shao (all members of the Product Development Decade of Vaccines Partner Agencies for Vaccines Advisory Committee, PDVAC) • For reviewers of the GVAP indicator on “licensure and Thomas Cherian (WHO), Angela Hwang (Bill & launch of at least one platform delivery technology” Melinda Gates Foundation), Lee Hall (National Institute (Indicator G4.2) (in alphabetical order as was done for of Allergy and Infectious Diseases), Peter Hansen (Gavi, PDVAC): Lauren Franzel, Michael Free, Sy Gebrekidan, the Vaccine Alliance), Jean-Marie Okwo-Bele (WHO), Birgitte Giersing, Nagwa Hasanin, Jim Janimak, Robin Nandy (UNICEF) Courtney Jarrahian, Debbie Kristensen, Tina Lorenson, Carsten Mantel, Ravi Menon, Hiro Okayasu, Liane Smith, Darin Zehrung (all members of the Decade of Vaccines Secretariat Immunization Practices Advisory Committee, IPAC, Delivery Technology working group, DTWG) Kamel Senouci, Daniela Urfer Strategic Advisory Group of Experts, Design and web production Decade of Vaccines working group Frédéric Bescond & Leopoldine Pozzo (Paprika), Oleru Huda Abason, Jon Kim Andrus, Narendra Hayatee Hasan, Kamel Senouci, Daniela Urfer Kumar Arora, Yagob Yousef Al-Mazrou, Alejandro Cravioto, Susan Elden, Marie-Yvette Madrid, Amani Abdelmoniem Mahmoud Mustafa, Rebecca Martin, Editorial assistance Kai Lashley (Further Consulting) page VI Acronyms and Abbreviations AEFI adverse events following immunization ANC1 first antenatal visit AFP acute flaccid paralysis aP a-cellular pertussis AVAREF African Vaccine Regulatory Forum BCG Bacille Calmette–Guérin (vaccine) BMGF Bill & Melinda Gates Foundation bNAbs broadly neutralizing antibodies CI confidence interval CCI Composite Coverage Index CFDA China Food and Drug Administration CMV cytomegalovirus cMYP comprehensive multi-year plan COIA Commission on Information and Accountability for Women’s and Children’s Health CRS congenital rubella syndrome CSO civil society organization CTC controlled temperature chain cVDPV circulating vaccine-derived poliovirus DCVRN Developing Countries Vaccine Regulators Network DHS Demographic and Health Survey DoV Decade of Vaccines DTP diphtheria–tetanus–pertussis (vaccine) EMA European Medicines Agency EPI Expanded Programme on Immunization EQA external quality assessment EWEC Every Woman Every Child FDA (US) Food and Drug Administration Gavi Global Alliance on Vaccines and Immunisation GACVS Global Advisory Committee on Vaccine Safety GPEI Global Polio Eradication Initiative GNI gross national income GVAP Global Vaccine Action Plan GVIRF Global Vaccine and Immunization Research Forum GVSI Global Vaccine Safety Initiative HA haemagglutinin HEAT Health Equity Assessment Toolkit HepB Hepatitis B Hib Haemophilus influenzae type b HPV human papillomavirus HSS health system strengthening IAVI International AIDS Vaccine Initiative IB-VPD invasive bacterial vaccine-preventable disease ICTRP International Clinical Trials Registry Platform iERG independent Expert Review Group IHR International Health Regulations IPAC Immunization Practices Advisory Committee IPV inactivated polio vaccine iTAG independent Technical Advisory Group IVB Immunization, Vaccines and Biologicals Department (WHO) JRF (WHO-UNICEF) joint reporting form KANCO Kenya AIDS NGOs Consortium LAIV live attenuated influenza vaccine LQA–CS lot quality assurance – cluster sampling M&E/A monitoring and evaluation/accountability M&RI Measles and Rubella Initiative page VII MenAfriVac serogroup A meningococcal conjugate vaccine MCV measles-containing vaccine MDG Millennium Development Goal MICS Multiple Indicator Cluster Surveys MR measles–rubella MMR measles–mumps–rubella MNT maternal and neonatal tetanus MNTE maternal and neonatal tetanus elimination MSF Médecins Sans Frontières Mtb Mycobacterium tuberculosis NGO nongovernmental organization NIAID National Institute of Allergy and Infectious Diseases NIH National Institutes of Health NITAG National Immunization Technical Advisory Group NRA national regulatory authority NVC National Verification Committee OECD Organisation for Economic Co-operation and Development OPV oral polio vaccine ORS oral rehydration salts PATH Program for Appropriate Technology in Health PAB protected at birth (against neonatal tetanus) PAHO Pan American Health Organization PCV pneumococcal conjugate vaccine PDVAC Product Development for Vaccines Advisory Committee PMNCH Partnership for Maternal, Neonatal and Child Health PQS performance, quality and safety QC quality control R&D research and development RCV rubella-containing vaccine RV rotavirus vaccine RSV respiratory syncytial virus RVC Regional Verification Commission SAGE Strategic Advisory Group of Experts (on immunization) SDG Sustainable Development Goal SHA Systems of Health Accounts SIA supplementary immunization activity SO (GVAP) Strategic Objective TAG Technical Advisory Group TPP target product profile TT tetanus toxoid TTCV tetanus toxoid-containing vaccines UN United Nations UNAIDS Joint United Nations Programme on HIV/AIDS UNICEF United Nations Children’s Fund UNICEF-SD United Nations Children’s Fund Supply Division V3P Vaccine Product, Price and Procurement (project) VFC (United States CDC) Vaccines for Children Fund VPD vaccine-preventable disease VPPAG Vaccine Presentation and Packaging Advisory Group VSV vesiculostomatitis
Load more

Recommended publications
  • ABSTRACT FROMEN, CATHERINE ANN. Monodisperse, Uniformly
    ABSTRACT FROMEN, CATHERINE ANN. Monodisperse, Uniformly-Shaped Particles for Controlled Respiratory Vaccine Delivery. (Under the direction of Joseph M. DeSimone). The majority of the world’s most infectious diseases occur at the air-tissue interface called the mucosa, including HIV/AIDS, tuberculosis, measles, and bacterial or viral gut and respiratory infections. Despite this, vaccines have generally been developed for the systemic immune system and fail to provide protection at the mucosal site. Vaccine delivery directly to the lung mucosa could provide superior lung protection for many infectious diseases, such as TB or influenza, as well as systemic and therapeutic vaccines for diseases such as Dengue fever, asthma, or cancer. Specifically, precision engineered biomaterials are believed to offer tremendous opportunities for a new generation of vaccines. The goal of this approach is to leverage naturally occurring processes of the immune system to produce memory responses capable of rapidly destroy virulent pathogens without harmful exposure. Considerable knowledge of biomaterial properties and their interaction with the immune system of the lung is required for successful translation. The overall goal of this work was to fabricate and characterize nano- and micro- particles using the Particle Replication In Non-wetting Templates (PRINT) fabrication technique and optimize them as pulmonary vaccine carriers. The main objectives of this PhD research included (1) the development of a calibration-quality aerosol system using PRINT, the application of these calibration-quality aerosols to improve understanding of (2) shaped aerosols under flow and (3) their cellular fate in the lung, and (4) the application of this knowledge towards the development of a mucosal vaccine.
    [Show full text]
  • Artículos Científicos
    Editor: NOEL GONZÁLEZ GOTERA Número 064 Diseño: Lic. Roberto Chávez y Liuder Machado. Semana 291212 - 040113 Foto: Lic. Belkis Romeu e Instituto Finlay La Habana, Cuba. ARTÍCULOS CIENTÍFICOS P ublicaciones incluidas en P ubMED durante el período comprendido entre el 29 de diciembre de 2012 y el 4 de enero de 2013. Total de artículos reuperados con “vaccin*” en título: 68 Vacunas meningococo (Neisseria meningitidis) 13. Up take of meningococcal va ccine in Arizona schoolchildren after implementation of school- entry immunization requirements. Simpson JE, Hills RA, Allwes D, Rasmussen L. Public Health Rep. 2013 Jan;128(1):37-45. PMID: 23277658 [PubMed - in process] Related citations 33. A cute Cerebellar Ataxia Following Meningococcal Group C Conjugate V accination. Cutroneo PM, Italiano D, Trifirò G, Tortorella G, Russo A, Isola S, Caputi AP, Spina E. J Child Neurol. 2012 Dec 28. [Epub ahead of print] PMID: 23275434 [PubMed - as supplied by publisher] Related citations 39. Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer m embrane vesicle va ccine against serogroup B meningococcal disease. Kaaijk P, van Straaten I, van de Waterbeemd B, Boot EP, Levels LM, van Dijken HH, van den Dobbelsteen GP. 1 Vaccine. 2012 Dec 27. doi:pii: S0264-410X(12)01815-4. 10.1016/j.vaccine.2012.12.031. [Epub ahead of print] PMID: 23273968 [PubMed - as supplied by publisher] Related citations 40. P riorities for research on meningocccal disease and the impact of serogroup A va ccination in the African meningitis belt. [No authors listed] Vaccine. 2012 Dec 27. doi:pii: S0264-410X(12)01820-8.
    [Show full text]
  • TB Vaccine R&D Roadmap Background Document
    TB Vaccine R&D Roadmap Background Document Version: 4.0 Date: 10.12.2020 This document summarizes the state-of-the-art in research and development for new vaccines for tuberculosis (TB). It is meant as a background document for a TB Vaccine Research & Development Roadmap and support the various consultations that are being held as part of the process of its development.a This background document seeks to provide an overview of the TB vaccine development goals, the current vaccine R&D pipeline, issues in clinical development, (new) directions in discovery and preclinical research, and considerations about moving vaccine candidates through the pipeline. It is meant as a living document, that will be updated as the Roadmap development process goes along. It is not meant to be exhaustive but to provide the reader with sufficient background to understand the Roadmap’s considerations and recommendations. For more detail the reader is referred to a number of recent reviews on the topic 1 2 3 4 5 6. The recommendations for TB vaccine R&D recently published by a number of stakeholders in have been added as Annex 17. LIST OF ABBREVIATIONS BCG Bacille Calmette-Guérin CHIM Controlled human infection model DS-TB Drug-susceptible tuberculosis IAVI International AIDS Vaccine Initiative IGRA Interferon-gamma release assay MDR-TB Multidrug-resistant tuberculosis MIP Mycobacterium indicus pranii Mtb Mycobacterium tuberculosis NHP Non-human primate PDP product Development Partnership PoD Prevention of Disease (clinical endpoint) PoI Prevention of Infection (clinical endpoint) PoR Prevention of Recurrence (clinical endpoint) PPC Preferred Product Characteristic R&D Research and development TB Tuberculosis TBVI Tuberculosis Vaccine Initiative TST Tuberculin skin test WHO World Health Organization a The TB Vaccine R&D Roadmap is being developed by the Amsterdam Institute for Global health and Development and the World Health organization, with financial support from the European & Developing Countries Clinical Trials Partnership (EDCTP).
    [Show full text]
  • Immunological Considerations for COVID-19 Vaccine Strategies
    REVIEWS Immunological considerations for COVID-19 vaccine strategies Mangalakumari Jeyanathan1,2,3,5, Sam Afkhami1,2,3,5, Fiona Smaill2,3, Matthew S. Miller1,3,4, Brian D. Lichty 1,2 ✉ and Zhou Xing 1,2,3 ✉ Abstract | The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) is the most formidable challenge to humanity in a century. It is widely believed that prepandemic normalcy will never return until a safe and effective vaccine strategy becomes available and a global vaccination programme is implemented successfully. Here, we discuss the immunological principles that need to be taken into consideration in the development of COVID-19 vaccine strategies. On the basis of these principles, we examine the current COVID-19 vaccine candidates, their strengths and potential shortfalls, and make inferences about their chances of success. Finally, we discuss the scientific and practical challenges that will be faced in the process of developing a successful vaccine and the ways in which COVID-19 vaccine strategies may evolve over the next few years. The coronavirus disease 2019 (COVID-19) outbreak constitute a safe and immunologically effective COVID-19 was first reported in Wuhan, China, in late 2019 and, at vaccine strategy, how to define successful end points the time of writing this article, has since spread to 216 in vaccine efficacy testing and what to expect from countries and territories1. It has brought the world to a the global vaccine effort over the next few years. This standstill. The respiratory viral pathogen severe acute Review outlines the guiding immunological principles respiratory syndrome coronavirus 2 (SARS-CoV-2) has for the design of COVID-19 vaccine strategies and anal- infected at least 20.1 million individuals and killed more yses the current COVID-19 vaccine landscape and the than 737,000 people globally, and counting1.
    [Show full text]
  • Modelling the Cost-Effectiveness of a New Infant Vaccine to Prevent Tuberculosis Disease in Children in South Africa Liezl Channing and Edina Sinanovic*
    Channing and Sinanovic Cost Effectiveness and Resource Allocation 2014, 12:20 http://www.resource-allocation.com/content/12/1/20 RESEARCH Open Access Modelling the cost-effectiveness of a new infant vaccine to prevent tuberculosis disease in children in South Africa Liezl Channing and Edina Sinanovic* Abstract Background: Tuberculosis remains the leading cause of death in South Africa. A number of potential new TB vaccine candidates have been identified and are currently in clinical trials. One such candidate is MVA85A. This study aimed to estimate the cost-effectiveness of adding the MVA85A vaccine as a booster to the BCG vaccine in children from the perspective of the South African government. Methods: The cost-effectiveness was assessed by employing Decision Analytic Modelling, through the use of a Markov model. The model compared the existing strategy of BCG vaccination to a new strategy in which infants receive BCG and a booster vaccine, MVA85A, at 4 months of age. The costs and outcomes of the two strategies are estimated through modelling the vaccination of a hypothetical cohort of newborns and following them from birth through to 10 years of age, employing 6-monthly cycles. Results: The results of the cost-effectiveness analysis indicate that the MVA85A strategy is both more costly and more effective – there are fewer TB cases and deaths from TB than BCG alone. The South African government would need to spend an additional USD 1,105 for every additional TB case averted and USD 284,017 for every additional TB death averted. The threshold analysis shows that, if the efficacy of the MVA85A vaccine was 41.3% (instead of the current efficacy of 17.3%), the two strategies would have the same cost but more cases of TB and more deaths from TB would be prevented by adding the MVA85A vaccine to the BCG vaccine.
    [Show full text]
  • Nonhuman Adenoviral Vector-Based Platforms and Their Utility in Designing Next Generation of Vaccines for Infectious Diseases
    viruses Review Nonhuman Adenoviral Vector-Based Platforms and Their Utility in Designing Next Generation of Vaccines for Infectious Diseases Marwa Alhashimi †, Ahmed Elkashif † , Ekramy E. Sayedahmed and Suresh K. Mittal * Immunology and Infectious Disease, and Purdue University Center for Cancer Research, Department of Comparative Pathobiology, Purdue Institute for Inflammation, College of Veterinary Medicine, Purdue University, West Lafayette, IN 47907-2027, USA; [email protected] (M.A.); [email protected] (A.E.); [email protected] (E.E.S.) * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: Several human adenoviral (Ad) vectors have been developed for vaccine delivery owing to their numerous advantages, including the feasibility of different vector designs, the robustness of elicited immune responses, safety, and scalability. To expand the repertoire of Ad vectors for receptor usage and circumvention of Ad vector immunity, the use of less prevalent human Ad types or nonhuman Ads were explored for vector design. Notably, many nonhuman Ad vectors have shown great promise in preclinical and clinical studies as vectors for vaccine delivery. This review describes the key features of several nonhuman Ad vector platforms and their implications in developing effective vaccines against infectious diseases. Citation: Alhashimi, M.; Elkashif, A.; Keywords: adenoviral vector; nonhuman adenoviral vector; viral vector; vaccine; infectious disease Sayedahmed, E.E.; Mittal, S.K. Nonhuman Adenoviral Vector-Based Platforms and Their Utility in Designing Next Generation of 1. Introduction Vaccines for Infectious Diseases. Adenoviruses (Ads) have been an invaluable tool for in vivo gene delivery, which has Viruses 2021, 13, 1493. https:// dramatically influenced the usefulness of Ad vectors for vaccine development and gene doi.org/10.3390/v13081493 therapy.
    [Show full text]
  • Frontrunners in the Race to Develop a SARS-Cov-2 Vaccine
    Canadian Journal of Microbiology Frontrunners in the race to develop a SARS-CoV-2 vaccine Journal: Canadian Journal of Microbiology Manuscript ID cjm-2020-0465.R1 Manuscript Type: Review Date Submitted by the 16-Nov-2020 Author: Complete List of Authors: Russell, Raquel; University of Manitoba, Department of Microbiology Pelka, Peter; University of Manitoba, Department of Microbiology Mark, Brian; University of Manitoba, Department of Microbiology Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV-2, Keyword: COVID-19,Draft vaccine development Is the invited manuscript for consideration in a Special Not applicable (regular submission) Issue? : © The Author(s) or their Institution(s) Page 1 of 91 Canadian Journal of Microbiology 1 2 3 Frontrunners in the race to develop a SARS-CoV-2 vaccine 4 5 Authors: Raquel L. Russell, Peter Pelka, Brian L. Mark 6 7 Affiliations: Department of Microbiology,Draft University of Manitoba, Winnipeg, 8 Manitoba, Canada, R3T2N2 9 10 Correspondence: Brian L. Mark, Ph.D., 11 email: [email protected] 12 tel: 1-204-480-1430 13 14 15 16 17 1 © The Author(s) or their Institution(s) Canadian Journal of Microbiology Page 2 of 91 1 Abstract 2 Numerous studies continue to be published on the COVID-19 pandemic that is being 3 caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Given the 4 rapidly evolving global response to SARS-CoV-2, here we primarily review the leading COVID- 5 19 vaccine strategies that are currently in Phase III clinical trials. Non-replicating viral vector 6 strategies, inactivated virus, recombinant protein subunit vaccines, and nucleic acid vaccine 7 platforms are all being pursued in an effort to combat the infection.
    [Show full text]
  • Cost-Effectiveness Analysis of Mva85a Vaccine: a New Tb Vaccine Candidate
    COST-EFFECTIVENESS ANALYSIS OF MVA85A VACCINE: A NEW TB VACCINE CANDIDATE by LIEZL BONNIN CHANNING CHNLIE001 SUBMITTED TO THE UNIVERSITY OF CAPE TOWN In partial fulfilment of the requirements for the degree ty of Cape Town Master of Public Health in Health Economics University of Cape Town (UCT) Universi August 2013 Supervisor: Dr Edina Sinanovic Health Economics Unit University of Cape Town South Africa The copyright of this thesis vests in the author. No quotation from it or information derived from it is to be published without full acknowledgement of the source. The thesis is to be used for private study or non- commercial research purposes only. Published by the University of Cape Town (UCT) in terms of the non-exclusive license granted to UCT by the author. University of Cape Town ty of Cape Town Universi DECLARATION I, Liezl Bonnin Channing (student number CHNLIE001), hereby declare that the work on which this dissertation/thesis is based is my original work (except where acknowledgements indicate otherwise) and that neither the whole work nor any part of it has been, is being, or is to be submitted for another degree in this or any other university. I empower the university to reproduce for the purpose of research either the whole or any portion of the contents in any manner whatsoever. Signature: Signature removed Date: 08 July 2013 ty of Cape Town Universi i Dedications To Dr Fareed Abdullah (affectionately known as “Dr”), thank you for taking a chance on me in 2003, for expanding my “pharmacist” horizons, for taking an interest in my professional development, and for investing in it, too! Without you, I would never have been exposed to the concepts of health economics, contemplated a degree in Public Health, or embarked upon a career in international health (financing!).
    [Show full text]
  • SUPPLEMENTARY INFORMATION Population Differences
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open 1 SUPPLEMENTARY INFORMATION 2 3 Population differences in vaccine responses (POPVAC): scientific rationale and cross-cutting 4 analyses for three linked, randomised controlled trials assessing the role, reversibility and 5 mediators of immunomodulation by chronic infections in the tropics 6 Gyaviira Nkurunungi1,¶,*, Ludoviko Zirimenya1,¶, Agnes Natukunda1,¶, Jacent Nassuuna1, Gloria 7 Oduru1, Caroline Ninsiima1, Christopher Zziwa1, Florence Akello1, Robert Kizindo1, Mirriam Akello1, 8 Pontiano Kaleebu1, Anne Wajja1, Henry Luzze2, Stephen Cose1,3, Emily L Webb4, Alison M Elliott1,5 for 9 the POPVAC trial team 10 11 1Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research 12 Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI and LSHTM) Uganda 13 Research Unit, Entebbe, Uganda 14 2Uganda National Expanded Program on Immunisation, Ministry of Health, Kampala, Uganda 15 3Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United 16 Kingdom 17 4MRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, London School 18 of Hygiene and Tropical Medicine, London, United Kingdom 19 ¶These authors contributed equally 20 *Correspondence: Gyaviira Nkurunungi; [email protected] Nkurunungi G, et al. BMJ Open 2021; 11:e040425. doi: 10.1136/bmjopen-2020-040425 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open 21 Table S1. Uganda National Expanded Programme on Immunisation (EPI) schedule Mode and site of Vaccine/ antigen Dosage and doses required Minimum Interval Between Doses Minimum Age to Start Storage Temperatures Administration Infant vaccines Infants (0-11m) 0.05ml.
    [Show full text]
  • SUPPLEMENTARY INFORMATION the Effect Of
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open 1 SUPPLEMENTARY INFORMATION 2 3 The effect of intensive treatment for schistosomiasis on immune responses to vaccines among 4 rural Ugandan island adolescents: randomised controlled trial protocol A for the ‘POPulation 5 differences in VACcine responses’ (POPVAC) programme 6 Gyaviira Nkurunungi1,¶,*, Ludoviko Zirimenya1,¶, Jacent Nassuuna1,¶, Agnes Natukunda1,¶, Prossy N 7 Kabuubi1, Emmanuel Niwagaba1, Gloria Oduru1, Grace Kabami1, Rebecca Amongin1, Alex Mutebe 1, 8 Milly Namutebi1, Christopher Zziwa1, Susan Amongi1, Caroline Ninsiima1, Caroline Onen1, Florence 9 Akello1, Moses Sewankambo1, Samuel Kiwanuka1, Robert Kizindo1, James Kaweesa2, Stephen Cose1,3, 10 Emily L Webb4, Alison M Elliott1,3 for the POPVAC trial team 11 12 1Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research 13 Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI and LSHTM) Uganda 14 Research Unit, Entebbe, Uganda 15 2Vector Control Division, Ministry of Health, Kampala, Uganda 16 3Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United 17 Kingdom 18 4MRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, London School 19 of Hygiene and Tropical Medicine, London, United Kingdom 20 ¶These authors contributed equally 21 *Correspondence: Gyaviira Nkurunungi; [email protected] Nkurunungi G, et al. BMJ Open 2021; 11:e040426. doi: 10.1136/bmjopen-2020-040426 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open Table S1.
    [Show full text]
  • New TB Vaccines: a Critical, Unmet Global Health Need
    v TB Vaccines: Pipeline Overview and Status of Late-stage Candidates Ann M. Ginsberg, MD, PhD PDVAC 27 June 2019 / Geneva New TB vaccines: a critical, unmet global health need • 10M new TB cases in 2017 300K HIV/AIDS TB Co-infection • 1.6M deaths 940K 1.6M HIV/AIDS • >1/4 of all AMR-related deaths and TB Deaths in 2017 Source: WHO Global TB Report 2018 2 PROGRESS Multiple Target Populations • Infants/children • Adolescents/Adults • TB patients – during or post-cure 4 Multiple Therapeutic Indications • Prevention of Infection – e.g., infant BCG replacement with improved BCG* • Prevention of TB disease • BCG replacement • BCG boost (proximal) • BCG boost (distal) • Prevention of recurrent TB • TB treatment shortening +/or increased cure rates (adjunct to treatment) * Under discussion with regulators 5 Overview of Global Pipeline Pre-Clinical Phase 1 Phase 2a Phase 2b Phase 3 Cysvac2 Ad5 Ag85A RUTI DAR-901 VaccaeTM U. Sydney, TBVI McMaster, CanSino Archivel Farma, S.L Dartmouth, GHIT Anhui Zhifei Longcom VPM 1002 BCG-ΔZMP1 ChAdOx185A/MVA85A TB/FLU-04L M72 + AS01E (ID/IM/Aerosol) SII, Max Planck, VPM, TBVI U. Zurich, TBVI, Aeras U. Oxford RIBSP GSK, Aeras (Phase 2/3) MVA-based Multiphasic Vaccine AEC/BC02 MTBVAC H56: IC31 MIP Transgene, TBVI Anhui Zhifei Longcom Biofabri, TBVI, Zaragoza SSI, Valneva, Aeras Cadila/ICMR ChAdOx1.85A/PPE15 U. Oxford, TBVI BCG Revac H64+CAF01 SSI, TBVI ID93 + GLA-SE IDRI, Wellcome Trust CMV-6Ag Aeras, Vir Biotech, OHSU Viral Vector Protein / Adjuvant ChAd3/MVA-5Ag Aeras, GSK, Transgene Mycobacterial – Inactivated
    [Show full text]
  • Safety and Efficacy of MVA85A, a New Tuberculosis Vaccine, in Infants Previously Vaccinated with BCG: a Randomised, Placebo-Controlled Phase 2B Trial
    Articles Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial Michele D Tameris*, Mark Hatherill*, Bernard S Landry, Thomas J Scriba, Margaret Ann Snowden, Stephen Lockhart, Jacqueline E Shea, J Bruce McClain, Gregory D Hussey, Willem A Hanekom, Hassan Mahomed†, Helen McShane†, and the MVA85A 020 Trial Study Team Summary Background BCG vaccination provides incomplete protection against tuberculosis in infants. A new vaccine, modified Published Online Vaccinia Ankara virus expressing antigen 85A (MVA85A), was designed to enhance the protective efficacy of BCG. We February 4, 2013 aimed to assess safety, immunogenicity, and efficacy of MVA85A against tuberculosis and Mycobacterium tuberculosis http://dx.doi.org/10.1016/ S0140-6736(13)60177-4 infection in infants. See Online/Comment http://dx.doi.org/10.1016/ Methods In our double-blind, randomised, placebo-controlled phase 2b trial, we enrolled healthy infants S0140-6736(13)60137-3 (aged 4–6 months) without HIV infection who had previously received BCG vaccination. We randomly allocated *Contributed equally infants (1:1), according to an independently generated sequence with block sizes of four, to receive one intradermal †Senior authors dose of MVA85A or an equal volume of Candida skin test antigen as placebo at a clinical facility in a rural region near South African Tuberculosis Cape Town, South Africa. We actively followed up infants every 3 months for up to 37 months. The primary study Vaccine Initiative, Institute of outcome was safety (incidence of adverse and serious adverse events) in all vaccinated participants, but we also Infectious Disease and Molecular Medicine and School assessed efficacy in a protocol-defined group of participants who received at least one dose of allocated vaccine.
    [Show full text]